The present article relates to the treatment of hematologic malignancies associated with high numbers of circu¬lating tumour cells by the administration of a therapeutically effective amount of an antibody that binds to the B-cell surface antigen Bp35 (CD20). The process involves the discovery that hematologic malignancies and, in particular, those characterized by high numbers of tumour cells in the blood may be effectively treated by the administration of a therapeutic anti-CD20 antibody. These malignancies include, in particular, CLL, B-PLL, and transformed non-Hodgkin’s lymphoma and also explains the commercial process of the manufacturing process of biological & antibodies and derivatives.
Patent Evaluation on Monoclonal Antibody (MAB) Therapy with Binding Specificity to CD20 B-Cell Surface Antigen Bp35 and the Manufacturing Process of Biological &Antibodies and Derivatives